PRPH vs. ABEO, PMVP, GNLX, ALLK, DMAC, SLS, ORMP, BTAI, MIST, and IOBT
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Abeona Therapeutics (ABEO), PMV Pharmaceuticals (PMVP), Genelux (GNLX), Allakos (ALLK), DiaMedica Therapeutics (DMAC), SELLAS Life Sciences Group (SLS), Oramed Pharmaceuticals (ORMP), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Abeona Therapeutics (NASDAQ:ABEO) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Abeona Therapeutics presently has a consensus target price of $36.00, indicating a potential upside of 937.46%. ProPhase Labs has a consensus target price of $11.00, indicating a potential upside of 131.09%. Given ProPhase Labs' higher possible upside, equities research analysts clearly believe Abeona Therapeutics is more favorable than ProPhase Labs.
80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 5.3% of Abeona Therapeutics shares are held by insiders. Comparatively, 26.1% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -37.81%. Abeona Therapeutics' return on equity of -29.83% beat ProPhase Labs' return on equity.
Abeona Therapeutics received 399 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
In the previous week, Abeona Therapeutics had 16 more articles in the media than ProPhase Labs. MarketBeat recorded 28 mentions for Abeona Therapeutics and 12 mentions for ProPhase Labs. Abeona Therapeutics' average media sentiment score of 0.71 beat ProPhase Labs' score of 0.08 indicating that ProPhase Labs is being referred to more favorably in the news media.
ProPhase Labs has higher revenue and earnings than Abeona Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.
Summary
Abeona Therapeutics beats ProPhase Labs on 9 of the 16 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
